Best Hospitals for Liver Cancer Treatment in Chennai, India

Liver cancer — most commonly hepatocellular carcinoma (HCC), which accounts for approximately 75–85% of all primary liver malignancies — arises from hepatocytes within a background of chronic liver disease, viral hepatitis (HBV/HCV), alcohol-related cirrhosis, or non-alcoholic steatohepatitis (NASH). HCC is the sixth most common cancer worldwide and the third leading cause of cancer-related death, underscoring the urgent need for expert, multidisciplinary management. The tumor disrupts hepatic parenchymal architecture, impairing the liver's critical functions — detoxification, protein synthesis (albumin, clotting factors), bile production, and glycogen storage — leading to progressive hepatic insufficiency, portal hypertension, and systemic complications including ascites, variceal bleeding, and hepatic encephalopathy.

• ELIGIBLE PATIENTS (Curative Intent):
• Solitary HCC ≤5 cm or up to 3 nodules each ≤3 cm with preserved liver function (Child-Pugh A or select Child-Pugh B) — eligible for surgical resection or ablation
• HCC within Milan criteria (single tumor ≤5 cm, or ≤3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread) — eligible for liver transplantation (living-donor or deceased-donor)
• HCC within UCSF criteria — may be considered for transplant at select high-volume centers
• Performance status ECOG 0–1 with adequate cardiopulmonary reserve for surgical candidates
• +23 more

Surgical APPROACHES:

1. Hepatic Resection (Hepatectomy): The gold-standard curative treatment for patients with solitary or oligofocal HCC and well-preserved liver function. Anatomic resection (removal of a defined hepatic segment or lobe) is preferred over non-anatomic wedge resection as it encompasses the portal territories supplying the tumor, reducing intrahepatic recurrence. Major hepatectomy (≥3 Couinaud segments) requires careful preoperative volumetric assessment and ICG testing. Robotic-assisted hepatectomy (Da Vinci Xi System) offers superior 3D magnification, tremor filtration, and articulating instruments for resections near the hepatic veins and inferior vena cava — reducing blood loss, transfusion requirements, and length of stay compared to open surgery. Laparoscopic hepatectomy is offered for peripheral, anterolateral-segment tumors. Intraoperative ultrasound (IOUS) with real-time contrast enhancement guides margin assessment.

2. Liver Transplantation: The only treatment that simultaneously removes the tumor and the underlying cirrhotic liver, addressing both the malignancy and the field defect that predisposes to recurrence. Outcomes are excellent for patients within Milan criteria (5-year survival >70%). Living-donor liver transplantation (LDLT) is a strength of leading Indian centers, where large volumes of LDLT reduce waiting times significantly compared to deceased-donor programs. Immunosuppression post-transplant uses calcineurin inhibitors (tacrolimus-based protocols) with mTOR inhibitors (everolimus) introduced for their potential anti-tumor properties.

Locoregional THERAPIES:

PHASE 1 — PRE-ARRIVAL WORKUP (Weeks 1–3, from home country):

• Patient submits medical records (imaging, pathology reports, lab work) to GAF Healthcare's clinical coordination team
• GAF's oncology panel conducts a virtual MDT review and issues a detailed treatment recommendation within 48–72 hours
• GAF assists with e-Medical visa application for India or UAE entry visa facilitation; visa processing typically takes 3–7 business days
• Patient books flights; GAF arranges airport pickup, hospital-adjacent accommodation for the patient and one attendant

PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–4):